{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:57Z","timestamp":1786982817510,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016796","name":"Adaptive Biotechnologies","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016796","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40487-021-00169-x","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T05:02:56Z","timestamp":1630731776000},"page":"607-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Cost Impact Analysis of clonoSEQ\u00ae as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany"],"prefix":"10.1007","volume":"9","author":[{"given":"Stefan","family":"Walzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4608-5380","authenticated-orcid":false,"given":"Sebastian","family":"Krenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,4]]},"reference":[{"key":"169_CR1","unstructured":"DGHO. Multiples Myelom. Leitlinie. Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h\u00e4matologischer und onkologischer Erkrankungen. Stand: Mai 2018. 2020. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/multiples-myelom\/@@guideline\/html\/index.html. Accessed 23 Aug 2021."},{"key":"169_CR2","unstructured":"Robert Koch-Institut (RKI). Krebs in Deutschland f\u00fcr 2015\/2016. 12. Ausgabe. Korrigierte Fassung vom 17.08.2020. 2020 23.08.2021]. 2021. https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/kid_2019\/krebs_in_deutschland_2019.pdf;jsessionid=1705F8DC8A337899291C5126135C696E.2_cid372?__blob=publicationFile."},{"issue":"12","key":"169_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/bmt.2016.222","volume":"51","author":"O Landgren","year":"2016","unstructured":"Landgren O, Devlin S, Boulad M, Mailankody S. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant. 2016;51(12):1565\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"169_CR4","unstructured":"DAG-KBT. LEITLINIEN zur autologen Stammzelltransplantation von der Deutschen Arbeitsgemeinschaft f\u00fcr Knochenmark- und Blutstammzelltransplantation (DAG-KBT). Version 1, Stand April 2018. 2018. https:\/\/www.dag-kbt.de\/files\/downloads\/Leitlinien_auto_Kap-3_SZT%20und%20Mobilisation.pdf. Accessed 23 Aug 2021."},{"issue":"14","key":"169_CR5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311\u201320.","journal-title":"N Engl J Med"},{"issue":"25","key":"169_CR6","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"M Roussel","year":"2014","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol. 2014;32(25):2712\u20137.","journal-title":"J Clin Oncol"},{"key":"169_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1182\/asheducation-2017.1.205","volume":"2017","author":"FE Davies","year":"2017","unstructured":"Davies FE. Is molecular remission the goal of multiple myeloma therapy? Hematology. 2017;2017:205\u201311.","journal-title":"Hematology"},{"issue":"1","key":"169_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2016","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2016;3(1):28\u201335.","journal-title":"JAMA Oncol"},{"key":"169_CR9","unstructured":"Adaptive Biotechnologies. clonoSEQ\u00ae assay B-cell reagent set instructions for use PNL-10047-04. 2021. p. 63."},{"key":"169_CR10","unstructured":"Robins HS, Carlson CS, Livingston RJ, Emerson RO, Sherwood AM, inventors; United States Patent No.: US 9,371,558 B2: Compositions and method for measuring and calibrating amplification basin multiplexed PCR reactions. US patent application. 2016."},{"key":"169_CR11","unstructured":"Robins HS, Carlson CS, Livingston RJ, Emerson RO, Sherwood AM, inventors; United States Patent No.: US 9,150,905 B2: Compositions and method for measuring and calibrating amplification basin multiplexed Pcr reactions. US patent application. 2015."},{"key":"169_CR12","first-page":"4685","volume":"130","author":"M Zimmermann","year":"2017","unstructured":"Zimmermann M, Kirsch I, Eckert B, Carlson J. Measurable residual disease testing in multiple myeloma using an improved testing technology: population impact. A clinical and budget impact analysis. Blood. 2017;130:4685.","journal-title":"Blood"},{"key":"169_CR13","unstructured":"Verband der Ersatzkassen e. V. (vdek). 2021 vdek-Basisdaten des Gesundheitswesens in Deutschland. 2021. https:\/\/www.vdek.com\/presse\/daten\/_jcr_content\/par\/publicationelement_1479644990\/file.res\/VDEK_Basisdaten2021_210x280_RZ_web.pdf. Accessed 23 Aug 2021."},{"key":"169_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","volume":"13","author":"A Briggs","year":"1998","unstructured":"Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13:397\u2013409.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"169_CR15","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","volume":"20","author":"H Avet-Loiseau","year":"2020","unstructured":"Avet-Loiseau H, Ludwig H, Landgren O, Paiva B, Morris C, Yang H, et al. Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis. Clin Lymphoma Myeloma Leuk. 2020;20(1):e30\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"169_CR16","unstructured":"European Medicines Agency (EMA). Guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies. Draft. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-use-minimal-residual-disease-clinical-endpoint-multiple-myeloma-studies_en.pdf. Accessed 23 Aug 2021."},{"issue":"32","key":"169_CR17","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(32):2456\u201364.","journal-title":"Blood"},{"issue":"8","key":"169_CR18","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"key":"169_CR19","unstructured":"Kassen\u00e4rztliche Bundesvereinigung (KBV). ONLINE-VERSION DES EBM. 2021. https:\/\/www.kbv.de\/html\/online-ebm.php. Accessed 23 Aug 2021."},{"key":"169_CR20","unstructured":"LAUER-FISCHER GmbH. Lauer Taxe 4.0. 2021. https:\/\/www.cgm.com\/lauer-fischer\/loesungen_lf\/lauer_taxe_lf\/lauertaxe_online_4_0\/online.de.jsp. Accessed 23 Aug 2021."},{"key":"169_CR21","unstructured":"European Medicines Agency (EMA). EPAR\u2014Product information. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/revlimid-epar-product-information_de.pdf. Accessed 23 Aug 2021."},{"key":"169_CR22","unstructured":"Amgen GmbH. Fachinformation (Zusammenfassung der Merkmale des Arzneimittels). Kyprolis\u00ae 10 mg\/30 mg\/60 mg Pulver zur Herstellung einer Infusionsl\u00f6sung. Stand. 2021. https:\/\/fachkreise.amgen.de\/x_download.php?t=f&n=1&id=526. Accessed 23 Aug 2021."},{"issue":"7","key":"169_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","volume":"36","author":"AE Attema","year":"2018","unstructured":"Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. Pharmacoeconomics. 2018;36(7):745\u201358.","journal-title":"Pharmacoeconomics"},{"key":"169_CR24","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Entwurf einer Methodik f\u00fcr die Bewertung von Verh\u00e4ltnissen zwischen Nutzen und Kosten im System der deutschen gesetzlichen Krankenversicherung. 2009. https:\/\/www.iqwig.de\/methoden\/09-03-18_entwurf_methoden_kosten-nutzen-bewertung_version_2_0.pdf?rev=180506. Accessed 23 Aug 2021."},{"key":"169_CR25","unstructured":"Greiner W, Witte J, Gensorowsky D, Pauge S. AMNOG-Report 2020. In: Storm A, editor. Beitr\u00e4ge zur Gesundheits\u00f6konomie und Versorgungsforschung (Band 32). Heidelberg: medhochzwei Verlag GmbH; 2020."},{"issue":"04","key":"169_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1055\/a-1468-7124","volume":"26","author":"L H\u00f6rster","year":"2021","unstructured":"H\u00f6rster L, Neusser S, Trautner A, Pahmeier K, Lax H, Merkel-Jens A, et al. Kosten der Nachsorge von Patienten mit h\u00e4matologischen Neoplasien. Gesundheits\u00f6konomie Qualit\u00e4tsmanagement. 2021;26(04):207\u201314.","journal-title":"Gesundheits\u00f6konomie Qualit\u00e4tsmanagement"},{"key":"169_CR27","unstructured":"Gemeinsamer Bundesauschuss (G-BA). Tragende Gr\u00fcnde zum Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschl\u00fcsse \u00fcber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V \u2013 Daratumumab (neues Anwendungsgebiet; Neubewertung eines Orphan Drugs nach \u00dcberschreitung der 50 Mio. Euro Grenze). Vom 15. 2018. https:\/\/www.g-ba.de\/downloads\/40-268-4804\/2018-02-15_AM-RL_XII_Daratumumab_D-310_TrG.pdf. Accessed 23 Aug 2021."},{"issue":"9","key":"169_CR28","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s10198-020-01219-3","volume":"21","author":"E Basic","year":"2020","unstructured":"Basic E, Kappel M, Misra A, Sellner L, Ratsch BA, Ostwald DA. Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany. Eur J Health Econ. 2020;21(9):1351\u201361.","journal-title":"Eur J Health Econ"},{"issue":"5","key":"169_CR29","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.1016\/j.clml.2020.01.001","volume":"20","author":"C Kunacheewa","year":"2020","unstructured":"Kunacheewa C, Lee H, Patel K, Thomas S, Amini B, Srour S, et al. Minimal residual disease negativity does not overcome poor prognosis in high-risk multiple myeloma: a single-center retrospective study. Clin Lymphoma Myeloma Leuk. 2020;20(5):e221\u201338.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-021-00169-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-021-00169-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-021-00169-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T09:36:15Z","timestamp":1636968975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-021-00169-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["169"],"URL":"https:\/\/doi.org\/10.1007\/s40487-021-00169-x","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,4]]},"assertion":[{"value":"12 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}